Given that obesity worsens outcomes of other glomerular disease beyond ORG, it is noteworthy that a recent trial of SGLT2 inhibition in glomerulonephritis patients showed higher proteinuria reduction with SGLT2 inhibition in patients with increased BMI (36, 75). Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.